5 Matching Annotations
  1. Last 7 days
  2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    Capivasertib combines with trastuzumab deruxtecan to enhance anti-tumour activity in HER2-positive and HER2-low tumours
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC13324342/
  3. Jan 2026
  4. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC12793832/
  5. Jul 2025
  6. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC12214875/
  7. Aug 2024
  8. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC11292196/
  9. Jan 2023
  10. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    AZD4625 is a Potent and Selective Inhibitor of KRASG12C
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC9538594/